While malignant mesothelioma is rare, it has limited therapeutic options. Even the best advances in treatment leave the median survival time period at about 12 months from diagnosis. However, increased knowledge and understanding of the molecular basis involved in cancer progression should aid in the discovery of biomarkers for earlier diagnosis. These biomarkers even have the potential to help scientists create more effective therapeutic tools for the disease. To read more about what the researchers from the New York University Medical Center found, click HERE.
